title: Accelerated clearance of Escherichia coli in experimental peritonitis of histamine-deficient mice.
abstract: We prepared a model of experimental peritonitis by introducing Escherichia coli into the peritoneal cavity of the histamine-deficient mice generated by a disruption of the gene for histidine decarboxylase (HDC), the unique histamine-synthesizing enzyme. When we inoculated E. coli into the peritoneal cavities of the HDC(-/-) (histamine-deficient) mice, they eliminated E. coli more efficiently than did the wild-type mice. Histamine was released efficiently from the peritoneal cells after E. coli inoculation in HDC(+/+) mice, although only trace amounts were detected in the peritoneal cells of HDC(-/-) mice. Two histamine agonists (6-[2-(4-imidazolyl)ethylamino]-N-(4-trifluoromethylphenyl)hepatanecarboxamide (H(1)) and dimaprit (H(2))) impaired the clearance of E. coli from the peritoneal cavity in HDC(-/-) mice, suggesting that the activation of both H(1) and H(2) receptors suppresses the clearance. In contrast, two kinds of H(1) and H(2) receptor antagonists, cimetidine and pyrilamine, promoted the clearance of E. coli in HDC(+/+) mice. Phagocytosis appeared to be enhanced in HDC(-/-) mice, since the number of neutrophils in the peritoneal cavity of HDC(-/-) mice was markedly increased. This enhanced recruitment of neutrophils was suppressed in the presence of the histamine agonists, 6-[2-(4-imidazolyl)ethylamino]-N-(4-trifluoromethylphenyl)hepatanecarboxamide and dimaprit. In this report histamine was first shown to be an important mediator in an E. coli infectious peritonitis model, causing a delay in the elimination of bacteria. This also raised the possibility of the use of antihistamine drugs for bacterial infection.
authors.affiliation: Departments of Cellular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Hori
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nihei
authors.forename: Yoshimochi
authors.initials: Y
authors.lastname: Kurokawa
authors.forename: Atsuo
authors.initials: A
authors.lastname: Kuramasu
authors.forename: Yoko
authors.initials: Y
authors.lastname: Makabe-Kobayashi
authors.forename: Tadashi
authors.initials: T
authors.lastname: Terui
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Doi
authors.forename: Susumu
authors.initials: S
authors.lastname: Satomi
authors.forename: Eiko
authors.initials: E
authors.lastname: Sakurai
authors.forename: Andras
authors.initials: A
authors.lastname: Nagy
authors.forename: Takehiko
authors.initials: T
authors.lastname: Watanabe
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ohtsu
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development / Q000276:immunology / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000276:immunology* / Q000382:microbiology*; D006632:Histamine / Q000235:genetics / Q000276:immunology*; D017442:Histamine Agonists / Q000494:pharmacology; D006633:Histamine Antagonists / Q000494:pharmacology; D006640:Histidine Decarboxylase / Q000172:deficiency / Q000235:genetics; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D010538:Peritonitis / Q000276:immunology* / Q000382:microbiology*; D010587:Phagocytosis / Q000187:drug effects
chemical_list: D017442:Histamine Agonists; D006633:Histamine Antagonists; D006632:Histamine; D006640:Histidine Decarboxylase